Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05962788 · ClinicalTrials.gov registry record · Phase 3
Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
A Phase 3 study, sponsored by Aurinia Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT05962788: Clinical Trial Phase 3 study, sponsored by Aurinia Pharmaceuticals.
NCT05962788 is a Phase 3 study that was terminated before completion, run by Aurinia Pharmaceuticals. The registered enrollment target is 4 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05962788, a Phase 3 study, was terminated before completion, sponsored by Aurinia Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of voclosporin for up to an additional 12 months following completion of treatment in the AUR-VCS-2020-03 study (VOCAL) in adolescent and pediatric subjects with lupus nephritis.
Primary Outcome
Incidence (subject counts and event counts) of TEAEs summarized by System Organ Class and Preferred Terms using MedDRA
Interventions
- DRUG voclosporin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2025-07-04 |
| Phase | Phase 3 |
Why NCT05962788 stopped before completion
NCT05962788 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which voclosporin is the first listed.
NCT05962788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05962788 about?
NCT05962788 is a clinical study titled "Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis". The purpose of this study is to assess the long-term safety and tolerability of voclosporin for up to an additional 12 months following completion of treatment in the AUR-VCS-2020-03 study (VOCAL) in adolescent and pediatric subjects with lupus nephritis.
What is the current status of trial NCT05962788?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2024-03-28. Estimated completion is 2025-07-04.
What interventions are being tested in trial NCT05962788?
The interventions under investigation include: voclosporin (DRUG).
Who is sponsoring clinical trial NCT05962788?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05962788's enrollment target sits among peer trials
4 1998th of 2000 higher than 2 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI